Medis has launched Atorvastatin immediately after the patent expiry this week to 18 customers in Austria, Germany, Denmark, France, the UK, Ireland, Italy, Netherlands and Sweden. Additionally, Atorvastatin is being marketed in Portugal and the product will be launched in Switzerland, South Africa and Australia in the near future. Atorvastatin is the generic equivalent of Pfizer’s Lipitor®/Zarator® the world’s top selling drug.
Valur Ragnarsson CEO Medis:”We have been fortunate to me meet considerable success with Atorvastatin sales to a number of partners in several markets, where the patent has already expired, during the last four years. So it is with great pleasure that we welcome the new markets, and especially to be able to support timely introduction upon patent expiry.”
Atorvastatin efficiently regulates the blood cholesterol levels and is one of the most effective drugs used in the therapy of primary hypercholesterolemia. Atorvastatin was developed by Medis parent company Actavis in Iceland and the product is primarily manufactured by the Company’s zero-carbon-footprint manufacturing site in Hafnarfjordur.